Patent Application
20210244780
The present invention relates to agents for modulating the expression of heat shock protein genes, medical and cosmetic compositions comprising the same, and methods for manufacturing and using such agents and compositions.
In recent years, research regarding the structure and metabolism of human skin has progressed, gradually clarifying the causes and mechanisms underlying age-related changes such as wrinkles, fine lines, blemishes, and sagging in human skin. Human skin is composed of a thin outer layer, i.e., the epidermis (epithelial tissue) and a thick dermis (connective tissue) as its lower layer. The epidermis, as the outermost layer of the body, protects the living body from the outside world and prevents internal moisture and nutrients from leaking to the outside world. The dermis is a connective tissue with a three-dimensionally spreading composite structure mainly composed of fibroblasts, collagen fibers (collagen), elastic fibers (elastin), and proteoglycans, and plays a role in providing strength, stretchability, and elasticity to the skin. As the amount of sebum and moisture in the skin decreases with aging, the moisturizing power of the stratum corneum on the skin surface is lost, and small wrinkles and skin roughness due to dryness or the like tend to occur. Prior research has identified several fermented products that can be used to improve skin health. Such findings are described, e.g., in International Patent Application Pub. No. WO2018/123828; Japanese Patent Nos. 5468183, 5467106, and 4990297; and Japanese Application Pub. Nos. 2015-156832, 2009-249365, and 2009-249366. Researchers in this area have also proposed that an extract of Arnica or the like may be administered to induce expression of a heat shock protein and provide a whitening effect. Such findings are described, e.g., in Japanese Patent No. 5697879.
In some aspects, the present disclosure provides agents for modulating expression of heat shock protein genes, as well as medical and cosmetic compositions comprising the same. In some aspects, the compositions described herein comprises a component derived from a natural source as an active ingredient and produce a wide range of therapeutic or other effects. In still further aspects, the disclosure provides methods for manufacturing and using the agents and compositions described herein, e.g., for modulating expression of a heat shock protein gene.
An agent for modulating expression of a heat shock protein gene according to one aspect of the present disclosure comprises a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. In some aspects, the medical or cosmetic compositions described herein comprise a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. Methods for manufacturing an agent for modulating expression of a heat shock protein gene according to some aspects of the present disclosure comprise obtaining a Lactobacillus sp. from Artemisia indica var. maximowiczii or Angelica keiskei.
Accordingly, in some aspects the disclosure provides agents for modulating expression of heat shock protein genes, medicaments and cosmetics comprising the same, and methods for manufacturing such agents and compositions. Such agents may comprise a component derived from a natural source as an active ingredient and may provide a wide range of therapeutic or other effects, e.g., when administered to a human subject.
Aspects of the present disclosure will be more specifically described below. Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims.
The agent for modulating expression of a heat shock protein (HSP) gene according to some aspects comprises a Lactobacillus sp., e.g., derived from Artemisia indica var. maximowiczii (Japanese mugwort) or Angelica keiskei (Ashitaba). The agent for modulating expression of a heat shock protein gene according to some aspects may advantageously promote expression of a heat shock protein (HSP) 70 gene, providing anti-aging effects (e.g., improving skin health in a human subject). The Lactobacillus sp. May be a species of the genus Lactobacillus and a gram-positive facultative anaerobic bacterium. Bacteria of the genus Lactobacillus ferment saccharides to produce lactic acid. Some members of the genus Lactobacillus reside in the body of an animal (e.g., in the gastrointestinal tract of a human). The Lactobacillus sp. according to some aspects is a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei.
For example, the Lactobacillus sp. according to some aspects is obtained by fermentation of Artemisia indica var. maximowiczii or Angelica keiskei. The agent for modulating expression of a heat shock protein gene according to some aspects may further comprise a fermentation liquid of Artemisia indica var. maximowiczii or Angelica keiskei.
Examples of the Lactobacillus sp. derived from Artemisia indica var. maximowiczii include L. parafarraginis, L. parabuchneri, L. buchneri, and L. harbinensis. Examples of the Lactobacillus sp. derived from Angelica keiskei include L. vini and L. nagelii. The agent for modulating expression of a heat shock protein gene according to some aspects may comprise a plurality of species of the Lactobacillus genus (e.g., any combination of the foregoing species).
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of the heat shock protein gene. Examples of the heat shock protein gene include an HSPA1A gene encoding HSP70 and an HSPB1 gene encoding HSP27. HSP70 promotes skin whitening, and also provides functional effects as an anti-blemish, anti-wrinkle, anti-stress, anti-cell death, and anti-inflammatory agent. HSP70 also plays a role in protecting cells and the gastric mucosa, and mitigates DNA repair disorders. HSP27 has anti-stress and wound healing functions. The agent for modulating expression of a heat shock protein gene according to some aspects comprises a Lactobacillus sp. derived from Angelica keiskei, and the agent promotes production of HSP47. HSP47 is a molecular chaperone involved in the biosynthesis of collagen. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of improving, for example, an anti-stress function, an anti-cell death function, an anti-inflammatory function, a cell-protecting function, a gastric mucosal protection function, an anti-DNA disorder function, and/or a wound healing function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food. In some aspects, the agent may be administered to a human subject to promote expression of a heat shock protein, promote skin whitening or wound healing, or to provide a variety of functional effects, including anti-blemish, anti-wrinkle, anti-stress, anti-cell death, anti-inflammatory, cell-protecting, gastric mucosal protection, and anti-DNA disorder functionality. It should be noted that the anti-wrinkle functionality may include the reduction of fine wrinkles in some aspects.
The agent for modulating expression of a heat shock protein gene according to some aspects also modulates expression of genes other than the heat shock protein gene. For example, the agent for modulating expression of a heat shock protein gene according to some aspects suppresses expression of an acid ceramide catabolic enzyme (ceramidase) gene. Examples of the acid ceramidase gene include an ASAH1 gene. The agent for modulating expression of a heat shock protein gene according to some aspects suppresses expression of an acid ceramidase, thus the agent is capable of, for example, promoting ceramide biosynthesis and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of suppressing expression of ceramidase, promoting ceramide biosynthesis, and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a lipid synthase gene. Examples of the lipid synthase gene include a DGAT1 gene. DGAT1 (Diacylglycerol O-acyltransferase 1) synthesizes neutral fat (TAG) from diacylglycerol (DAG). DGAT1-deficient mice exhibit abnormalities in skin barrier function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting lipid synthesis and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting lipid synthesis and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a lysosomal hydrolase gene. Lysosome is involved in degradation of saccharides and glycolipids in cells. Lysosome requires a lysosomal hydrolase to perform the function. Examples of the lysosomal hydrolase gene include an acid β-glucosidase (GBA) gene. In patients with lysosomal disease, the activity of GBA is reduced or deficient. In addition, activation of GBA improves skin barrier function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, preventing and treating lysosomal disease, and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting lysosomal hydrolase expression, improving lysosomal function, preventing lysosomal disease, treating lysosomal disease, and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a tight junction biosynthesis factor gene. Examples of the tight junction biosynthesis factor gene include a claudin 1 (CLDN1) gene and an occludin (OCLN) gene. Claudin and occludin are components of the tight junction. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting biosynthesis of tight junction and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a tight junction biosynthesis factor, promoting expression of claudin, promoting expression of occludin, promoting biosynthesis of tight junction, and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an intercellular adhesion factor gene. Examples of the intercellular adhesion factor gene include an integrin α2 (ITGA2) gene, an E-cadherin (CDH1) gene, and a hyaluronic acid receptor (CD44) gene. Integrin, cadherin, and CD44 contribute to intercellular adhesion. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting biosynthesis of an intercellular adhesion factor and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting biosynthesis of an intercellular adhesion factor, promoting expression of integrin, promoting expression of cadherin, promoting expression of a hyaluronic acid receptor, and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a temperature-sensitive transient receptor potential (TRP) channel gene. Examples of the TRP channel gene include a TRPV3 gene. TRPV3 is involved in proliferation and differentiation of keratinocytes that maintain epidermal barrier function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting biosynthesis of a keratinocyte and improving skin barrier function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a TRP channel, promoting biosynthesis of a keratinocyte, and improving barrier function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an anti-microbial molecule gene. Examples of the anti-microbial molecule gene include a Toll-like receptor 2 (TLR2) gene. Toll-like receptors have functions of sensing microbes and activating immunity. Further examples of the anti-microbial molecule gene include a DEFB1 gene, a DEFB4A gene, and a DEFB103A gene. The DEFB1, DEFB4A, and DEFB103A genes encode β-defensins, such as anti-microbial peptides DEFB1, DEFB2, and DEFB103. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving anti-microbial function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a Toll-like receptor, promoting expression of a β-defensin, and improving anti-microbial function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a sirtuin gene. Examples of the sirtuin gene include a SIRT4 gene. The activity of the sirtuin gene improves anti-aging function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving anti-aging function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of sirtuin and improving anti-aging function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a telomerase gene. Examples of the telomerase gene include a TERT gene and a TERC gene. Promoting the activity of telomerases increases cell life. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving anti-aging function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a telomerase and improving anti-aging function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an energy metabolizing factor gene. Examples of the energy metabolizing factor gene include a PPARGC1A gene. The PPARGC1A gene encodes peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1). PGC-1 promotes energy metabolism. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving energy metabolic function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of an energy metabolizing factor, promoting expression of PGC-1, and improving energy metabolic function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a hyaluronic acid biosynthesis factor gene. Examples of the hyaluronic acid biosynthesis factor gene include a hyaluronic acid synthase 1 (HAS1) gene, a hyaluronic acid synthase 2 (HAS2) gene, and a hyaluronic acid synthase 3 (HAS3) gene.
The agent for modulating expression of a heat shock protein gene according to some aspects suppresses expression of a hyaluronic acid degradation factor gene. Examples of the hyaluronic acid degradation factor gene include a hyaluronic acid degradation enzyme 2 (HYAL2) gene and a cell migration-inducing and hyaluronan-binding protein (CEMIP, KIAA1199) gene.
Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving hyaluronic acid biosynthesis function. Hyaluronic acid is effective in preventing and treating osteoarthritis, improving moisturizing function, removing sagging, and reducing wrinkles. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, preventing and treating osteoarthritis, improving moisturizing function, and reducing sagging and wrinkles. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a hyaluronic acid synthase enzyme, suppressing expression of a hyaluronic acid degradation factor, promoting biosynthesis of hyaluronic acid, preventing osteoarthritis, treating osteoarthritis, improving moisturizing function, improving anti-sagging function, and improving anti-wrinkle function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a basal membrane biosynthesis factor gene. Examples of the basal membrane biosynthesis factor gene include a laminin αI (LAMA1) gene, a laminin α5 (LAMAS) gene, a collagen type IV αI (COL4A1) gene, and a collagen type VII αI (COL7A1). The agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting biosynthesis of laminin and collagen and promoting biosynthesis of a basal membrane. The agent for modulating expression of a heat shock protein gene according to some aspects can be used as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of, for example, promoting expression of a basal membrane biosynthesis factor, promoting expression of laminin, promoting expression of collagen, and promoting biosynthesis of a basal membrane.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of collagen type I. Collagen type I provides elasticity to bone. Collagen type I provides strength to skin. The agent for modulating expression of a heat shock protein gene according to some aspects can be used as a medicament, a cosmetic, and/or a food for promoting expression of collagen type I.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a matrix metalloproteinase inhibitor gene. Examples of the matrix metalloproteinase inhibitor gene include a TIMP1 gene. Matrix metalloproteinase inhibitors inhibit matrix metalloproteinase and suppress degradation of extracellular matrix. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, suppressing degradation of extracellular matrix. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a matrix metalloproteinase inhibitor and suppressing degradation of extracellular matrix.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an anti-oxidation factor gene. Examples of the anti-oxidant factor gene include a superoxide dismutase 3 (SOD3) gene, a catalase (CAT) gene, a glutathione reductase (GSR) gene, a glutathione peroxidase 1 (GPX1) gene, and a metallothionein 1F (MT1F) gene. SOD is an enzyme that degrades active oxygen. CAT is an enzyme that degrades hydrogen peroxide. GSR is an enzyme that reduces oxidative glutathione. GPX1 is an enzyme that degrades hydrogen peroxide. MT1F is an anti-oxidation protein. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving anti-oxidation function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of an anti-oxidation factor gene, promoting expression of SOD, promoting expression of CAT, promoting expression of GSR, promoting expression of GPX1, promoting expression of MT1F, and improving anti-oxidation function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an interleukin 1 receptor antagonist molecule (IL1RN) gene. Deficiency of interleukin-1 receptor antagonist molecules results in deficiency of interleukin-1 receptor antagonist (DIRA). Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of preventing and treating DIRA. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of an interleukin 1 receptor antagonist, preventing DIRA, and treating DIRA.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a semaphorin-in gene. Examples of the semaphorin-in gene include a SEMA3A gene. Semaphorin-in is a repulsive guidance factor that exhibits a repulsive effect on neuroaxis extension. Semaphorin suppresses angiogenesis. Semaphorin controls bone mass. Semaphorin-in suppresses itching. Semaphorin has prophylactic and therapeutic effects on atopic dermatitis. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, repulsively guiding neuroaxis extension, suppressing angiogenesis, controlling bone mass, suppressing itching, and preventing and treating atopic dermatitis. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of semaphorin-in, suppressing extension of neuroaxis, suppressing angiogenesis, controlling bone mass, suppressing itching, preventing atopic dermatitis, and treating atopic dermatitis.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a nerve growth factor (NGF) gene and a nerve growth factor receptor (NGFR). Nerve growth factors promote nerve growth and maintenance, promote restoration of cranial nerve function, and are effective in preventing and treating Alzheimer's disease and dementia. Nerve growth factors express effects through neuronal growth factor receptors. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting expression of a nerve growth factor, promoting growth and maintenance of a nerve, promoting restoration of cranial nerve function, and preventing and treating Alzheimer's disease and dementia. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of a nerve growth factor, promoting growth and maintenance of a nerve, promoting restoration of cranial nerve function, preventing Alzheimer's disease, treating Alzheimer's disease, preventing dementia, and treating dementia.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a nuclear factor κB (NFκB) inhibitor gene. Examples of the NFκB inhibitor gene include a NFκBIA gene. NFκB inhibitors, such as IκBα, inhibit NFκB activity and prevent and treat cancer. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, preventing and treating cancer. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of an NFκB inhibitor, preventing cancer, and treating cancer.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a calpastatin (CAST) gene. The calpastatin is a calpain (CAPN) inhibitory protein. In aged cells, CAPN is activated, and CAST disappears. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, suppressing aging. The agent for modulating expression of a heat shock protein gene according to some aspects can be used as a medicament, a cosmetic, and/or a food for an application selected from the group consisting of promoting expression of a CAPN inhibitory protein and improving anti-aging function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a citrullinated protein activation factor gene. Examples of the citrullinated protein activator gene include peptidyl arginine deiminase 3 (PAD3). PADs activate citrullinated proteins and advance normal epidermal keratinization. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, advancing normal skin keratinization. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for an application selected from the group consisting of promoting expression of a citrullinated protein activator and advancing normal skin keratinization.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of a transglutaminase gene. Examples of the transglutaminase gene include a TGM1 gene. Transglutaminase increases the physical strength of skin surface and enhances moisturizing function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, increasing skin surface strength or improving skin moisturizing function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for an application selected from the group consisting of promoting expression of transglutaminase, improving skin surface strength, improving skin firmness, and improving skin moisturizing function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an involucrin (IVL) gene. IVL promotes cornified envelope maturation and improves skin moisturizing function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, promoting cornified envelope maturation and improving skin moisturizing function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of IVL, promoting cornified envelope maturation, and improving skin moisturizing function.
The agent for modulating expression of a heat shock protein gene according to some aspects promotes expression of an aquaporin gene. Examples of the aquaporin gene include an AQP3 gene. Aquaporin is involved in the migration of keratinocytes and improves skin moisturizing function. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects is capable of, for example, improving keratinocyte migration function and improving skin moisturizing function. The agent for modulating expression of a heat shock protein gene according to some aspects can be used, for example, as a medicament, a cosmetic, and/or a food for at least one application selected from the group consisting of promoting expression of aquaporin, improving keratinocyte migration function, and improving skin moisturizing function.
The agent for modulating expression of a heat shock protein gene according to some aspects also has a function of reducing fungus (mold). The agent for modulating expression of a heat shock protein gene according to some aspects, for example, reduces fungus by 80% or more, 85% or more, 90% or more, or 95% or more within 24 hours. Examples of the fungus include, but are not limited to, Trichophyton, Candida, Cryptococcus, and Aspergillus. The agent for modulating expression of a heat shock protein gene according to some aspects also has a therapeutic effect on mycosis. Examples of the mycosis include, but are not limited to, trichophytosis, candidiasis, cryptococcosis, and aspergillosis.
The agent for modulating expression of a heat shock protein gene according to some aspects also has a function of reducing gram-negative bacterium and gram-positive bacterium. The agent for modulating expression of a heat shock protein gene according to some aspects, for example, reduces gram-negative bacterium and gram-positive bacterium by 80% or more, 85% or more, 90% or more, or 95% or more within 24 hours. Examples of the gram-negative bacterium include, but are not limited to, Escherichia coli, Salmonella enterica, Vibrio enteritidis, Bacillus pneumoniae, and Pseudomonas aeruginosa. Examples of the gram-positive bacterium include, but are not limited to, methicillin-resistant Staphylococcus aureus (MRSA), spore-forming Bacillus cereus, and Bacillus subtilis.
The agent for modulating expression of a heat shock protein gene according to some aspects also has an anti-viral function. The agent for modulating expression of a heat shock protein gene according to some aspects, for example, reduces viral load by 80% or more, 85% or more, 90% or more, or 95% or more within 24 hours of administration to a human subject. The virus may be an enveloped virus, which is a virus with an envelope, or a non-enveloped virus, which is a virus without an envelope. Agents according to the present disclosure may be administered as a therapeutic for DNA and RNA viruses.
Examples of the DNA virus with an envelope include, but are not limited to, human herpes virus, vaccinia virus, and hepatitis B virus.
Examples of the RNA virus with an envelope include, but are not limited to, influenza virus, SARS coronavirus, RS virus, mumps virus, Lassa virus, dengue virus, rubella virus, human immunodeficiency virus, measles virus, hepatitis C virus, Ebola virus, yellow fever virus, and Japanese encephalitis virus.
Examples of the DNA virus without an envelope include, but are not limited to, adenovirus, B19 virus, papova virus, and human papilloma virus.
Examples of the RNA virus without an envelope include, but are not limited to, norovirus, polio virus, echovirus, hepatitis A virus, hepatitis E virus, rhinovirus, astrovirus, rotavirus, coxsackievirus, enterovirus, and sapovirus.
The agent for modulating expression of a heat shock protein gene according to some aspects contains an effective amount of a Lactobacillus sp. The agent for modulating expression of a heat shock protein gene according to some aspects may comprise the Lactobacillus sp. in a solvent such as water or in a fermentation liquid (e.g., of a plant). Examples of the plant for obtaining the fermentation liquid include Artemisia indica var. maximowiczii or Angelica keiskei, as in the Lactobacillus sp. For example, an agent for modulating expression of a heat shock protein gene according to some aspects may be a Lactobacillus sp. obtained by fermenting Artemisia indica var. maximowiczii or Angelica keiske, and isolating the Lactobacillus sp. present in the fermentation liquid. In some aspects, the Lactobacillus sp. may be administered in the fermentation liquid, whereas in others the Lactobacillus sp. may be purified and/or isolated from the fermentation liquid and administered.
The effective amount is an amount necessary to exhibit a gene expression modulation effect. The effective amount is appropriately determined depending on a gene of interest. Generally, as the concentration of the Lactobacillus sp. increases (e.g., in a solvent comprising plant fermentation liquid), a greater effect is observed on the modulation of gene expression following administration of the Lactobacillus sp. However, for example, in the case where the gene of interest is a GBA gene, the lower the concentration of the Lactobacillus sp., the greater the effect on modulation of expression of the gene is exhibited. Furthermore, for example, in the case where the gene of interest is a TLR2 gene, a solvent containing no plant fermentation liquid leads to a greater effect on modulating expression of the gene, as compared to an otherwise identical concentration of Lactobacillus sp. administered in a solvent containing plant fermentation liquid.
The Lactobacillus sp. contained in the agent for modulating expression of a heat shock protein gene according to some aspects may be a live bacterium, or may be a dead bacterium, for example, a heat-treated bacterium. Thus, the agent for modulating expression of a heat shock protein gene according to some aspects may contain a dead bacterium of the Lactobacillus sp. The Lactobacillus sp. may be a dried bacterial product. The dead bacterium or dried bacterial product of the Lactobacillus sp. also has a gene expression modulation effect and an anti-bacterial anti-viral effect. The dead bacterium or dried bacterial product of the L Lactobacillus sp. is easy to transport and store for a long time.
The agent for modulating expression of a heat shock protein gene according to some aspects can be, for example, a liquid, a cream, an ointment, a plaster, a gel, a wax, or a spray.
The agent for modulating expression of a heat shock protein gene according to some aspects can be, for example, a cosmetic for skin conditioning. Examples of the cosmetic for skin conditioning include a lotion, an essence, and a pack. The agent for modulating expression of a heat shock protein gene according to some aspects can be, for example, a cosmetic for protection. Examples of the cosmetic for protection include an emulsion for protection and a cream for protection. The agent for modulating expression of a heat shock protein gene according to some aspects can be, for example, a base makeup cosmetic. Examples of the base makeup cosmetic include a foundation, a powder, and a foundation primer. The agent for modulating expression of a heat shock protein gene according to some aspects can be, for example, a point makeup cosmetic. Examples of the point makeup cosmetic include a lipstick, an eye makeup, a cheek, and a nail enamel.
The agent for modulating expression of a heat shock protein gene according to some aspects is provided as, for example, a disinfectant, a dermatological agent such as a therapeutic ointment agent, an eye drop, or an oral medicine. The agent for modulating expression of a heat shock protein gene according to some aspects is administered to, for example, skin of a human body including a finger, a toe, a hand, and a foot, a hair, an oral cavity, and an eye.
The agent for modulating expression of a heat shock protein gene can contain, in addition to the Lactobacillus sp., a formulation component of cosmetic and medicament, such as a liquid fat, a solid fat, a wax, a hydrocarbon, a higher fatty acid, a higher alcohol, an ester, a silicone, an anionic surfactant, a cationic surfactant, an amphoteric surfactant, a non-ionic surfactant, a moisturizing agent, a water-soluble polymer, a thickening agent, a coating agent, a metal ion blocking agent, a lower alcohol, a polyhydric alcohol, a saccharide, an amino acid, an organic amine, a pH adjusting agent, a skin nutrient, a vitamin, an anti-oxidant, a fragrance, a powder, a coloring material, and water, depending on the purpose, as desired.
In the case where the agent for modulating expression of a heat shock protein gene according to some aspects contains an oily component, the concentration of the oily component in the agent for modulating expression of a heat shock protein gene according to some aspects is not particularly limited, but, for example, is 0.1% by mass or more and 90% by mass or less, or 0.5% by mass or more and 90% by mass or less. In the case where the agent for modulating expression of a heat shock protein gene according to some aspects contains an aqueous component, the concentration of the aqueous component in the agent for modulating expression of a heat shock protein gene according to some aspects is not particularly limited, but, for example, is 0.1% by mass or more and 90% by mass or less, or alternatively 0.5% by mass or more and 90% by mass or less. The ratio of the oily component to the aqueous component in the agent for modulating expression of a heat shock protein gene according to some aspects is appropriately set depending on whether the agent for modulating expression of a heat shock protein gene according to some aspects is an oil-in-water (O/W) agent or a water-in-oil (W/O) agent. In the case where the agent for modulating expression of a heat shock protein gene according to some aspects contains a surfactant, the concentration of the surfactant in the agent for modulating expression of a heat shock protein gene according to some aspects is not particularly limited, and, for example, is 2% by mass or more and 10% by mass or less.
The agent for modulating expression of a heat shock protein gene according to some aspects may contain, as appropriate, an anti-bacterial substance or anti-viral substance according to the purpose, in addition to the Lactobacillus sp.
The agent for modulating expression of a heat shock protein gene according to some aspects is produced by fermenting a plant to obtain a fermentation liquid containing the Lactobacillus sp. When the plant is fermented, salt and saccharides such as molasses are added to the plant. The fermentation temperature is, for example, 30° C. The hydrogen ion index (pH) of the resulting fermentation liquid is around 4.0. Secretions of the Lactobacillus sp. may be extracted from the fermentation liquid.
The obtained fermentation liquid may be heated to make the Lactobacillus sp. contained in the fermentation liquid into a dead bacterium. The fermentation liquid may also be spray-dried to obtain a dried bacterial product of the Lactobacillus sp. The dried bacterial product can also be prepared by a lyophilization method, a hot-air drying method, or the like.
Furthermore, the obtained fermentation liquid, a bacterial cell of the Lactobacillus sp., or a dried bacterial product of the Lactobacillus sp. may be added to soy milk, and the soy milk may be fermented to obtain a soy milk fermentation liquid. In some aspects, the soy milk fermentation liquid also has a gene expression modulation effect.
In some aspects, the agent for modulating expression of a heat shock protein gene or the like, according to the present disclosure, may be prepared or formulated as described herein (e.g., according to the following examples). Such agents may display any of the effects or functionality described herein.
The agents for modulating expression of a heat shock protein gene, medicaments and/or cosmetics according to the present disclosure may comprise a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. In some aspects, such agents and compositions may further comprise a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei. The medicament may be an anti-wrinkle medicament or an anti-aging medicament. The cosmetic may be an anti-wrinkle cosmetic or an anti-aging cosmetic.
The present disclosure provides a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei, which is used for modulating expression of a heat shock protein gene. The present disclosure provides a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei, which may be used for modulating expression of a heat shock protein gene.
The present disclosure provides methods for using a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei, and methods for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic. The present disclosure further provides methods for using a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei, and for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic.
The present disclosure provides methods for modulating expression of a heat shock protein gene, treatment methods, and cosmetic methods, comprising administering to a human or a non-human animal a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. The present disclosure also provides methods for modulating expression of a heat shock protein gene, treatment methods, and cosmetic methods, comprising administering to a human or a non-human animal a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei. The treatment method may provide therapeutic and/or cosmetic effects (e.g., anti-wrinkle or anti-aging effects).
The heat shock protein gene can be at least one gene selected from the group consisting of an HSPA1A gene and an HSPB1 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one selected from the group consisting of the HSPA1A gene and the HSPB1 gene.
The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may modulate expression of a gene other than a heat shock protein gene. The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei may be at least one selected from the group consisting of a ceramidase gene, a lipid synthase gene, a lysosomal hydrolase gene, a tight junction biosynthesis factor gene, and an intercellular adhesion factor gene.
The ceramidase gene may be an ASAH1 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may suppress expression of the ASAH1 gene.
The lipid synthase gene may be a DGAT1 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of the DGAT1 gene.
The lysosomal hydrolase gene may be a GBA gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of the GBA gene.
The tight junction biosynthesis factor gene may be at least one gene selected from the group consisting of a CLDN1 gene and an OCLN gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one selected from the group consisting of the CLDN1 gene and the OCLN gene.
The intercellular adhesion factor gene may be at least one gene selected from the group consisting of an ITGA2 gene, a CDH1 gene, and a CD44 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei may promote expression of at least one selected from the group consisting of the ITGA2 gene, the CDH1 gene, and the CD44 gene.
The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be an anti-microbial molecule gene. The anti-microbial molecule gene may be at least one gene selected from the group consisting of a TLR2 gene, a DEFB1 gene, a DEFB4A gene, and a DEFB103A gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one gene selected from the group consisting of the TLR2 gene, the DEFB1 gene, the DEFB4A gene, and the DEFB103A gene.
The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be at least one gene selected from the group consisting of a sirtuin gene and a telomerase gene.
The sirtuin gene may be a SIRT4 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of the SIRT4 gene.
The telomerase gene may be at least one gene selected from the group consisting of a TERT gene and a TERC gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one gene selected from the group consisting of the TERT gene and the TERC gene.
The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be an energy metabolizing factor gene. The energy metabolizing factor gene may be a PPARGC1A gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of the PPARGC1A gene.
The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be at least one gene selected from the group consisting of a hyaluronic acid biosynthesis factor gene and a hyaluronic acid degradation factor gene.
The hyaluronic acid biosynthesis factor gene may be at least one gene selected from the group consisting of a HAS1 gene, a HAS2 gene, and a HAS3 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one selected from the group consisting of the HAS1 gene, the HAS2 gene, and the HAS3 gene.
The hyaluronic acid degradation factor gene may be at least one gene selected from the group consisting of a HYAL2 gene and a CEMIP gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may suppress expression of at least one selected from the group consisting of the HYAL2 gene and the CEMIP gene.
The gene of which expression is modulated by the Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be a basal membrane biosynthesis factor gene. The basal membrane biosynthesis factor gene may be at least one gene selected from the group consisting of a LAMA1 gene, a LAMAS gene, a COL4A1 gene, and a COL7A1 gene. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may promote expression of at least one selected from the group consisting of the LAMA1 gene, the LAMAS gene, the COL4A1 gene, and the COL7A1 gene.
The agent for modulating expression of a heat shock protein gene, the medicament, or the cosmetic according to the present disclosure promotes production of collagen type I. The agent for promoting production of collagen type I according to the present disclosure contains a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei. The agent for promoting production of collagen type I according to the present disclosure contains a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei.
The present disclosure provides a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei, which is used for promoting production of collagen type I. The present disclosure provides a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei, which are used for promoting production of collagen type I.
The present disclosure provides methods of using a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei for manufacturing an agent for promoting production of collagen type I. The present disclosure provides methods of using a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei for manufacturing an agent for promoting production of collagen type I.
The present disclosure provides methods for promoting production of collagen type I, comprising administering a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei to a human or a non-human animal. The present disclosure also provides methods for promoting production of collagen type I, comprising administering a Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei and a fermentation liquid derived from Artemisia indica var. maximowiczii or Angelica keiskei to a human or a non-human animal.
The agent for modulating expression of a heat shock protein gene, the medicament, or the cosmetic according to the present disclosure may promote production of HSP47. The agent for promoting production of HSP47 according to the present disclosure may contain a Lactobacillus sp. derived from Angelica keiskei. The agent for promoting production of HSP47 according to the present disclosure may contain a Lactobacillus sp. derived from Angelica keiskei and a fermentation liquid derived from Angelica keiskei.
The present disclosure provides a Lactobacillus sp. derived from Angelica keiskei, which may be used for promoting production of HSP47. The present disclosure also provides a Lactobacillus sp. derived from Angelica keiskei and a fermentation liquid derived from Angelica keiskei, which may be used for promoting production of HSP47.
The present disclosure provides methods of using a Lactobacillus sp. derived from Angelica keiskei, for manufacturing an agent for promoting production of HSP47. The present disclosure provides methods of using a Lactobacillus sp. derived from Angelica keiskei and a fermentation liquid derived from Angelica keiskei, for manufacturing an agent for promoting production of HSP47.
The present disclosure provides methods for promoting production of HSP47, comprising administering a Lactobacillus sp. derived from Angelica keiskei to a human or a non-human animal. The present disclosure provides methods for promoting production of HSP47, comprising administering a Lactobacillus sp. derived from Angelica keiskei and a fermentation liquid derived from Angelica keiskei to a human or a non-human animal.
The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be selected from the group consisting of L. parafarraginis, L. parabuchneri, L. buchneri, L. harbinensis, L. vini, and/or L. nagelii.
The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be a dead bacterium. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be subjected to a heat treatment. The Lactobacillus sp. derived from Artemisia indica var. maximowiczii or Angelica keiskei according to the present disclosure may be a dried bacterial product.
The methods for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic according to the present disclosure may comprise a step of obtaining a Lactobacillus sp. from Artemisia indica var. maximowiczii or Angelica keiskei. The method for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic according to the present disclosure may further comprise fermenting Artemisia indica var. maximowiczii or Angelica keiskei to obtain a fermentation liquid. The method for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic according to the present disclosure may further comprise making the obtained Lactobacillus sp. into a dead bacterium. The method for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic according to the present disclosure may further comprise subjecting the obtained Lactobacillus sp. to a heat treatment. The method for manufacturing an agent for modulating expression of a heat shock protein gene, a medicament, or a cosmetic according to the present disclosure may further comprise drying the obtained Lactobacillus sp.
Hereinafter, non-limiting examples of the present disclosure are described to illustrate selected aspects of the agents, compositions, and methods described herein.
It is believed that the number of lactic acid bacteria in the leaves of Artemisia indica var. maximowiczii reaches a maximum point during 2 hours (1 hour before sunrise and 1 hour after sunrise). In addition, it is believed that the lactic acid bacteria decrease and the photosynthetic bacteria increase outside of this time period. Thus, during this two-hour window, the portions about 20 cm from the tips of the leaves of Artemisia indica var. maximowiczii were harvested. 6.3 kg of the harvested leaves of Artemisia indica var. maximowiczii were immediately placed in a first pickle barrel with a plastic bag placed inside. 3.2 kg of molasses and 0.6 kg of coarse salt were sprinkled into the leaves of Artemisia indica var. maximowiczii, and then the opening of the plastic bag was closed and sealed. A heavy stone was placed on the top of the plastic bag, and the leaves of Artemisia indica var. maximowiczii were pickled.
A several days after the pickle juice had risen to the top of the leaves of Artemisia indica var. maximowiczii, the heavy stone was removed. Then, 10 L of water without chlorine for rinsing out was added to a second pickle barrel, and the pickle of the leaves of Artemisia indica var. maximowiczii and 10 kg of the pickle juice were added into the water. In addition, a third pickle barrel was prepared, and a wire net filter was placed on the opening of the third pickle barrel. From the second pickle barrel, the leaves of Artemisia indica var. maximowiczii were removed little by little while rubbing and washing them by hands, and the leaves of Artemisia indica var. maximowiczii were gently pressed by the palm of the hand against the wire net filter on the opening of the third pickle barrel to squeeze the pickle juice.
After squeezing all of the leaves of Artemisia indica var. maximowiczii, the pickle juice remaining in the second pickle juice was filtered through the wire net filter. Next, into the pickle juice in the third pickle barrel, molasses (Hateruma brown sugar) was melted so that the final concentration was 10% by weight, and coarse salt was melted so that the final concentration was 3% by weight. The fermentation was then started by setting the ambient temperature of the third pickle barrel to about 30° C. Foaming with large foams was first confirmed, then the foaming was gradually turned into foaming with fine foams, and finally the foaming was ceased. The pH when the foaming was ceased after about a week was around 3.8. The pickle juice at this time was used as a fermentation liquid of Artemisia indica var. maximowiczii. A portion of the obtained fermentation liquid of Artemisia indica var. maximowiczii was heated at 70° C. for 30 minutes to obtain a heat-treated fermentation liquid of Artemisia indica var. maximowiczii in which the bacteria were dead.
Analysis of the non-heat-treated fermentation liquid of Artemisia indica var. maximowiczii by a next-generation sequencer (MiSeq, Illumina, Inc.) showed, as shown in
It is believed that the number of lactic acid bacteria in the leaves of Angelica keiskei reaches a maximum point during a window beginning 2 hours before, and ending 1 hour after, sunrise. In addition, it is supposed that, the lactic acid bacteria decrease and the photosynthetic bacteria increase outside of the time period. Thus, during this three-hour window, the leaf stems of the sprouts of Angelica keiskei were harvested. 6.3 kg of the harvested Angelica keiskei were immediately placed in a first pickle barrel with a plastic bag placed inside. 3.2 kg of molasses and 0.6 kg of coarse salt were sprinkled into the Angelica keiskei, and then the opening of the plastic bag was closed and sealed. A heavy stone was placed on the top of the plastic bag and the Angelica keiskei was pickled.
A several days after the pickle juice had risen to the top of the Angelica keiskei, the heavy stone was removed. Then, 10 L of water without chlorine for rinsing out was added to a second pickle barrel, and the pickle of the Angelica keiskei and 10 kg of the pickle juice were added into the water. In addition, a third pickle barrel was prepared, and a wire net filter was placed on the opening of the third pickle barrel. From the second pickle barrel, the Angelica keiskei was removed little by little while rubbing and washing it by hands, and the Angelica keiskei was gently pressed by the palm of the hand against the wire net filter on the opening of the third pickle barrel to squeeze the pickle juice.
After squeezing all of the Angelica keiskei, the pickle juice remaining in the second pickle juice was filtered through the wire net filter. Next, into the pickle juice in the third pickle barrel, molasses was melted so that the final concentration was 10% by weight, and coarse salt was melted so that the final concentration was 3% by weight. The fermentation was then started by setting the ambient temperature of the third pickle barrel to about 30° C. Foaming with large foams was first confirmed, then the foaming was gradually turned into foaming with fine foams, and finally the foaming was ceased. The pH when the foaming was ceased after about a week was around 4.0. The pickle juice at this time was used as a fermentation liquid of Angelica keiskei. A portion of the obtained fermentation liquid of Angelica keiskei was heated at 70° C. for 30 minutes to obtain a heat-treated fermentation liquid of Angelica keiskei in which the bacteria were dead.
Analysis of the non-heat-treated fermentation liquid of Angelica keiskei by a next-generation sequencer (MiSeq, Illumina, Inc.) showed that the fermentation liquid of Angelica keiskei contained a vini species, a nagelii species and the like, as shown in
Soy milk was heated to 70° C., and superheated and sterilized for about 30 minutes. To the heat-sterilized treated soy milk, the non-heat-treated fermentation liquid of Artemisia indica var. maximowiczii prepared in Example 1 was added such that the final concentration was about 10% by weight, and the mixture was sufficiently stirred. Subsequently, the soy milk to which the non-heat-treated fermentation liquid of Artemisia indica var. maximowiczii was added was fermented at 37° C. for 24 hours. After fermentation, the solids were removed by filtration to obtain a soy milk fermentation liquid containing a Lactobacillus sp.
A live Lactobacillus sp. was isolated from the fermentation liquid of Artemisia indica var. maximowiczii obtained in Example 1, then dispersed in pure water at a concentration of 0.05 g/L, and the obtained dispersion was taken as Sample 1. The isolated live Lactobacillus sp. was dispersed in pure water at a concentration of 5.0 g/L, and the obtained dispersion was taken as Sample 2. A fermentation liquid of Artemisia indica var. maximowiczii containing the live Lactobacillus sp. at a concentration of 5.0 g/L was taken as Sample 3.
A three-dimensional culture epidermal model (SkinEtchic RHE: 18 RHE 098, EPISKIN, Inc.) was conditioned overnight using a growth medium (Growth Medium: 18 SGM 082, EPISKIN, Inc.). The three-dimensional culture epidermal model was then transferred to a transwell insert (Corning) of a six-well plate dispensed with the growth medium, and 504 of one of Samples 1 to 3 was applied to the stratum corneum side of the three-dimensional culture epidermal model in the well. After 24 hours, the medium to which the sample was added was removed from the well, and the three-dimensional culture epidermal model was washed with phosphate buffered saline (PBS(−)) free of calcium and magnesium.
The three-dimensional culture epidermal model was cut together with the membrane from the transwell insert using a scalpel, and the three-dimensional culture epidermal model was immersed in a lysate (QIAzol(R), QIAGEN), and then the cells were crushed using a crushing device (Tissue Lyser, QIAGEN) to obtain a crushed solution. RNA was purified from the crushed solution using an RNA purification kit (miRNeasy Mini Kit(R), QIAGEN) to collect purified RNA. The collected RNA was sent to Mitsubishi Chemical Co., Ltd., which provided contract analysis services, and gene expression in cells treated with the sample was analyzed using an mRNA expression analysis chip. Gene expression in cells not treated with the sample (control) was normalized to 1.00, and the ratio of gene expression in the cells treated with the sample to gene expression in control was calculated. A significance difference test was also performed using a Student's t-test.
The results are shown in
A fermentation liquid of Artemisia indica var. maximowiczii containing the Lactobacillus sp. prepared in Example 1 at a concentration of 5.0 g/L was applied to the cheek of a 46-year-old woman twice daily for 5 months. As a result, it was confirmed that wrinkles with aging were reduced as shown in
Staphylococcus aureus and MRSA were prepared as gram-positive cocci. Bacillus subtilis and Bacillus cereus were prepared as gram-positive rod. Escherichia coli, Salmonella enterica, Vibrio enteritidis, and Bacillus pneumoniae were prepared as gram-negative cocci. Pseudomonas aeruginosa was prepared as gram-negative rod.
To the soy milk fermentation liquid containing 10 mL of the Lactobacillus sp. prepared in Example 3, 0.1 mL of a bacterial solution containing any one of the above bacteria at a concentration of 107 cells/mL was inoculated and allowed to react at 25° C., and the bacterial viability of the inoculated bacteria over time was measured for 24 hours. Also, as a control, 0.1 mL of the bacterial solution was inoculated into 10 mL of 1/15 mol/L phosphate buffer of pH 7.2, and allowed to react at 25° C., and the bacterial viability of the inoculated bacteria over time was measured for 24 hours. As a result, as shown in
Trichophyton and Candida were prepared as fungi. To the soy milk fermentation liquid containing 10 mL of the Lactobacillus sp. prepared in Example 3, 0.1 mL of a bacterial solution containing Trichophyton or Candida at a concentration of 107 cells/mL was inoculated and allowed to react at 25° C., and the bacterial viability of the inoculated bacteria over time was measured for 24 hours. Also, as a control, 0.1 mL of the bacterial solution was inoculated into 10 mL of 1/15 mol/L phosphate buffer of pH 7.2, and allowed to react at 25° C., and the bacterial viability of the inoculated bacteria over time was measured for 24 hours. As a result, as shown in
A culture solution of influenza virus type A (H1N1) was prepared as an envelope virus. In addition, a culture solution of norovirus (feline calicivirus) was prepared as a non-envelope virus. The culture solution of virus was serially diluted by 10-fold with purified water. An anti-viral test with the soy milk fermentation liquid containing the Lactobacillus sp. prepared in Example 3 was then performed at room temperature according to 50% tissue culture infectious dose (TCID 50). The anti-viral test was conducted at the Japan Food Research Laboratories.
As a result, the soy milk fermentation liquid containing the Lactobacillus sp. reduced the infectious titer of influenza virus within 1 hour as shown
The non-heat-treated fermentation liquid of Artemisia indica var. maximowiczii obtained in Example 1 was spray-dried to obtain dried bacterial cells of the Lactobacillus sp. The obtained dried bacterial product was suspended in water and glycerin so that the dried bacterial product was 10 parts by weight to obtain a suspension of the Lactobacillus sp. of Example 9. The suspension of the Lactobacillus sp. was added to Trichophyton, and the colony-forming unit (CFU) of Trichophyton was measured. As a result, the suspension of the Lactobacillus sp. killed Trichophyton within 24 hours as shown in
Normal human dermal fibroblasts were maintained using a DMEM medium (+5% FBS) in an incubator until confluent. After reaching confluence, the medium was removed from the incubator. DMEM (0% FBS) containing 600 μmol/L of hydrogen peroxide (H2O2) was then added to the incubator, and the cells were cultured at 37° C. for 1 hour. After 1 hour of culturing, the H2O2-containing DMEM (0% FBS) was removed from the incubator, and then a DMEM medium (+10% FBS) was added to the incubator. After these procedures were repeated for 4 days, the cells were cultured with DMEM (10% FBS) for an additional 3 days, and the obtained cells were used as aging induction-treated cells.
The aging induction of the cells was confirmed by staining with senescence-associated beta-galactosidase (SA-β-Gal), an aging marker.
The aging induction-treated cells were seeded in a 48-hole plate at a cell density of 5.0×104 cells/well using a DMEM medium (+5% FBS). Twenty-four hours after seeding, the medium was replaced with each of a DMEM medium (+0.5% FBS) containing the non-heat-treated fermentation liquid of Artemisia indica var. maximowiczii prepared in Example 1 at concentrations of 1.0% and 10.0%, a DMEM medium (+0.5% FBS) containing the non-heat-treated fermentation liquid of Angelica keiskei prepared in Example 2 at concentrations of 1.0% and 10.0%, a DMEM medium (+0.5% FBS) containing Vitamin C magnesium phosphate at 25 μmol/L, a DMEM medium (+0.5% FBS) containing Vitamin C at 25 μmol/L, and a DMEM medium (+0.5% FBS). The cells were then cultured for 48 hours, and then the medium was collected. The cells were washed with PBS(−), then trypsinized, and were collected from the plate. The collected cells were sonicated, and the resulting cell lysate was centrifuged at 15000 rpm to collect the supernatant.
The amount of collagen type I in the collected medium was quantified by an ELISA method (direct method using anti-human collagen type I antibody (rabbit)). As a result, as shown in
In addition, HSP47 in the supernatant of the cell lysate was quantified using a commercially available ELISA kit (abcam). As a result, it was shown that culturing cells in a medium to which the fermentation liquid of Angelica keiskei was added promoted production of HSP47 as shown in
Normal human dermal fibroblasts were seeded in a six-hole plate at a cell density of 5.0×105 cells/well using a DMEM medium (+5% FBS), and the cells were cultured for 24 hours.
The medium of each well was removed. DMEM (0% FBS) containing 600 μmol/L of hydrogen peroxide (H2O2) was then added to the well, and the cells were cultured at 37° C. for 1 hour to induce aging of the cells. After 1 hour of culture, the H2O2-containing DMEM (0% FBS) was removed from the wells, then each of a DMEM medium (+10% FBS) containing 1.0% of the fermentation liquid of Artemisia indica var. maximowiczii containing the Lactobacillus sp. prepared in Example 1 at a concentration of 5.0 g/L, a DMEM medium (+10% FBS) containing 1.0% of the fermentation liquid of Angelica keiskei containing the Lactobacillus sp. prepared in Example 2 at a concentration of 5.0 g/L, a DMEM medium (+10% FBS) containing 10 μmol/L of resveratrol, which has an anti-oxidation effect, as a positive control, and a DMEM medium (+10% FBS) as a negative control was added to the wells. These procedures were repeated for 4 days.
Subsequently, each of a DMEM medium (+10% FBS) containing 1.0% of the fermentation liquid of Artemisia indica var. maximowiczii containing the Lactobacillus sp. prepared in Example 1 at a concentration of 5.0 g/L, a DMEM medium (+10% FBS) containing 1.0% of the fermentation liquid of Angelica keiskei containing the Lactobacillus sp. prepared in Example 2 at a concentration of 5.0 g/L, a DMEM medium (+10% FBS) containing 10 μmol/L of resveratrol, which has an anti-oxidation effect, as a positive control, and a DMEM medium (+10% FBS) as a negative control was added to the wells, and the cells were cultured for 3 days.
The cells cultured under each condition were then seeded in a 48-hole plate at a cell density of 5.0×104 cells/well, and the cells were cultured for 24 hours. The cells were then immobilized with PBS containing 3% formaldehyde. The solution in the well was then replaced with a reaction solution at pH 6 containing 1 mg/mL of 5-bromo-4-chloro-3-indolyl-D-galactoside (X-Gal), and the wells were allowed to stand still for 12 to 16 hours. Microscopic observation was then performed, and staining with senescence-associated beta-galactosidase (SA-β-Gal), an aging marker, was observed.
As a result, the cells induced aging alone had a strong degree of SA-β-Gal staining, as shown in
A three-dimensional culture epidermal model (SkinEthic RHE: 19RHE 008, EPISKIN, Inc.) was conditioned overnight in a growth medium (Growth Medium: 19SGM 005, EPISKIN, Inc.). After conditioning, the epidermal model was transferred to a 6-hole plate dispensed with 1 mL of the growth medium, and each of 50 μL of the fermentation liquid of Artemisia indica var. maximowiczii containing the Lactobacillus sp. prepared in Example 1 at a concentration of 5.0 g/L and 50 μL of the fermentation liquid of Angelica keiskei containing the Lactobacillus sp. prepared in Example 2 at a concentration of 5.0 g/L was applied to the stratum corneum side of the epidermal model.
The epidermal model was cultured for 24 hours, and then the fermentation liquid was removed, and the epidermal model was washed with PBS(−). The viability of the epidermal model was assessed using an Alamer Blue method. A maintenance medium containing 10% Alamer Blue reagent (alamarBlue Cell Viability Reagent(R), Invitrogen, Inc.) was dispensed into a 24-hole plate. The epidermal model was transferred to the plate, and cultured for 2 hours, and then the fluorescence intensity of the culture supernatant was measured. The cell viability was calculated as an index (%) to the fluorescence intensity of the control group to which PBS(−) was applied in place of the fermentation liquid. The obtained results were subjected to a significance test using a Student t test. As a result, as shown in
After the fluorescence intensity was measured, the epidermal model was immersed in PBS, and the epidermal model was crushed using a sample crusher (Tissue Lyser). The cell lysate was centrifuged at 15000 rpm, and the supernatant was collected. The HSP70 in the collected solution was quantified using a commercially available ELISA kit (Enzo Life Sciences, Inc.). The obtained results were subjected to a significance test using a Student t test. As a result, the amount of HSP70 produced was significantly increased by the application of the fermentation liquid of Artemisia indica var. maximowiczii or the fermentation liquid of Angelica keiskei as shown in
The above-described aspects and examples are for ease of understanding the present disclosure, and are non-limiting. The present invention may be modified/improved without departing from its spirit, and the present disclosure also includes equivalents thereof. In other words, those in which a skilled person in the art has made appropriate design changes to each of some aspects and examples are also encompassed within the scope of the present invention as long as they have the features of the present invention. For example, the various elements included in some aspects and the examples are not limited to those illustrated, and can be changed as appropriate. Furthermore, some aspects and examples each are exemplary, and it goes without saying that partial substitutions or combinations of the configurations shown in different aspects are possible and those are also encompassed within the scope of the present disclosure.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2018-203795 | Oct 2018 | JP | national |
The present application is a continuation of International Patent Application No. PCT/JP2019/038560, filed Sep. 30, 2019, which claims priority to Japanese Patent Application No. 2018-203795, filed Oct. 30, 2018, the entire contents of each of which are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/JP2019/038560 | Sep 2019 | US |
| Child | 17243708 | US |
